Boston Scientific Co. (BSX) EVP Kevin J. Ballinger Sells 68,486 Shares

Boston Scientific Co. (NYSE:BSX) EVP Kevin J. Ballinger sold 68,486 shares of the firm’s stock in a transaction on Monday, June 11th. The stock was sold at an average price of $34.12, for a total transaction of $2,336,742.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Kevin J. Ballinger also recently made the following trade(s):

  • On Monday, May 7th, Kevin J. Ballinger sold 31,056 shares of Boston Scientific stock. The stock was sold at an average price of $30.00, for a total transaction of $931,680.00.

Shares of NYSE:BSX traded up $0.97 on Thursday, hitting $32.70. The stock had a trading volume of 532,850 shares, compared to its average volume of 8,243,987. Boston Scientific Co. has a twelve month low of $24.54 and a twelve month high of $37.30. The company has a debt-to-equity ratio of 0.68, a quick ratio of 0.59 and a current ratio of 0.82. The company has a market capitalization of $47.36 billion, a PE ratio of 25.80, a P/E/G ratio of 2.45 and a beta of 0.77.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, April 25th. The medical equipment provider reported $0.33 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.32 by $0.01. Boston Scientific had a net margin of 1.21% and a return on equity of 25.10%. The company had revenue of $2.38 billion for the quarter, compared to the consensus estimate of $2.34 billion. During the same quarter in the previous year, the company earned $0.29 EPS. The firm’s revenue for the quarter was up 10.1% compared to the same quarter last year. analysts forecast that Boston Scientific Co. will post 1.39 EPS for the current year.

Several institutional investors have recently added to or reduced their stakes in the stock. Commonwealth Equity Services LLC raised its holdings in shares of Boston Scientific by 2.7% in the first quarter. Commonwealth Equity Services LLC now owns 71,279 shares of the medical equipment provider’s stock valued at $1,947,000 after buying an additional 1,850 shares during the last quarter. Moneta Group Investment Advisors LLC raised its holdings in shares of Boston Scientific by 2.1% in the first quarter. Moneta Group Investment Advisors LLC now owns 92,525 shares of the medical equipment provider’s stock valued at $2,528,000 after buying an additional 1,925 shares during the last quarter. Wealthfront Inc. raised its holdings in shares of Boston Scientific by 7.8% in the first quarter. Wealthfront Inc. now owns 28,785 shares of the medical equipment provider’s stock valued at $786,000 after buying an additional 2,083 shares during the last quarter. Oppenheimer Asset Management Inc. raised its holdings in shares of Boston Scientific by 5.9% in the first quarter. Oppenheimer Asset Management Inc. now owns 38,234 shares of the medical equipment provider’s stock valued at $1,044,000 after buying an additional 2,143 shares during the last quarter. Finally, State Treasurer State of Michigan raised its holdings in shares of Boston Scientific by 0.6% in the first quarter. State Treasurer State of Michigan now owns 404,796 shares of the medical equipment provider’s stock valued at $11,059,000 after buying an additional 2,300 shares during the last quarter. 89.02% of the stock is owned by institutional investors and hedge funds.

A number of equities research analysts have weighed in on the stock. ValuEngine upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating in a research note on Monday. Argus lifted their price target on shares of Boston Scientific from $32.00 to $36.00 and gave the stock a “buy” rating in a research note on Thursday, June 7th. Zacks Investment Research upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating and set a $34.00 price target on the stock in a research note on Monday, May 21st. TheStreet upgraded shares of Boston Scientific from a “c” rating to an “a-” rating in a research note on Tuesday, May 29th. Finally, Jefferies Financial Group reiterated a “hold” rating and set a $31.00 price target on shares of Boston Scientific in a research note on Thursday, April 26th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, eighteen have assigned a buy rating and three have issued a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $32.39.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

Insider Buying and Selling by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit